Literature DB >> 25666484

Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.

Hirotaka Iwase1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25666484     DOI： 10.1007/s10147-015-0795-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


× No keyword cloud information.
  22 in total

1.  Influence of Synthetic Oestrogens on Advanced Malignant Disease.

Authors:  A Haddow; J M Watkinson; E Paterson; P C Koller
Journal:  Br Med J       Date:  1944-09-23

Review 2.  Tamoxifen in the treatment of breast cancer.

Authors:  C K Osborne
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

3.  Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.

Authors:  M J Byrne; V Gebski; J Forbes; M H Tattersall; R J Simes; A S Coates; J Dewar; M Lunn; C Flower; P G Gill; J Stewart
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

4.  Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.

Authors:  Alessandra Gennari; PierFranco Conte; Riccardo Rosso; Cinzia Orlandini; Paolo Bruzzi
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

Review 5.  Optimizing the treatment of metastatic breast cancer.

Authors:  Julie R Gralow
Journal:  Breast Cancer Res Treat       Date:  2005       Impact factor: 4.872

6.  Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.

Authors:  J F R Robertson; A Howell; V A Gorbunova; T Watanabe; T Pienkowski; M R Lichinitser
Journal:  Breast Cancer Res Treat       Date:  2005-07       Impact factor: 4.872

7.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.

Authors:  Anthony Howell; John F R Robertson; Paul Abram; Mikhail R Lichinitser; Richard Elledge; Emilio Bajetta; Toru Watanabe; Charles Morris; Alan Webster; Isaiah Dimery; C Kent Osborne
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

8.  Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.

Authors:  Z U Rahman; D K Frye; T L Smith; L Asmar; R L Theriault; A U Buzdar; G N Hortobagyi
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

9.  Is breast cancer survival improving?

Authors:  Sharon H Giordano; Aman U Buzdar; Terry L Smith; Shu-Wan Kau; Ying Yang; Gabriel N Hortobagyi
Journal:  Cancer       Date:  2004-01-01       Impact factor: 6.860

10.  Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors:  Denise A Yardley; Shinzaburo Noguchi; Kathleen I Pritchard; Howard A Burris; José Baselga; Michael Gnant; Gabriel N Hortobagyi; Mario Campone; Barbara Pistilli; Martine Piccart; Bohuslav Melichar; Katarina Petrakova; Francis P Arena; Frans Erdkamp; Wael A Harb; Wentao Feng; Ayelet Cahana; Tetiana Taran; David Lebwohl; Hope S Rugo
Journal:  Adv Ther       Date:  2013-10-25       Impact factor: 3.845
View more
  4 in total

1.  The effect of royal jelly on the growth of breast cancer in mice.

Authors:  Shuang Zhang; Qiqi Shao; Haiyang Geng; Songkun Su
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

2.  The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.

Authors:  Wakako Tajiri; Hideki Ijichi; Katsumi Takizawa; Yumiko Koi; Takanobu Masuda; Hiroki Ueo; Chinami Koga; Yoshiaki Nakamura; Kenichi Taguchi; Masahiro Okamoto; Eriko Tokunaga
Journal:  Breast Cancer       Date:  2020-06-29       Impact factor: 4.239

3.  Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer.

Authors:  Kanako Hagio; Toraji Amano; Hideyuki Hayashi; Takashi Takeshita; Tomohiro Oshino; Junko Kikuchi; Yoshihito Ohhara; Ichiro Yabe; Ichiro Kinoshita; Hiroshi Nishihara; Hiroko Yamashita
Journal:  Sci Rep       Date:  2021-04-14       Impact factor: 4.379

4.  Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.

Authors:  Mai Tomiguchi; Yutaka Yamamoto; Mutsuko Yamamoto-Ibusuki; Lisa Goto-Yamaguchi; Yoshitaka Fujiki; Saori Fujiwara; Aiko Sueta; Mitsuhiro Hayashi; Takashi Takeshita; Touko Inao; Hirotaka Iwase
Journal:  Cancer Sci       Date:  2016-03-28       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.